StreetAlpha.app
Home › Stocks › PMN

ProMIS Neurosciences Inc. (PMN)

$3.16
▼ −1.56%
LAST CLOSE · NOV 20

ProMIS Neurosciences develops antibody therapies that target harmful misfolded proteins in neurodegenerative diseases such as Alzheimer's. It last closed at $3.16 on Nov 20, down 1.56% on the day. The next earnings report for PMN is expected around Wed, Mar 24, 2027. For the quarter ended Sep 2026, PMN reported EPS of -$0.89. Over its last 8 reports the stock moved an average of 2.7% the session after earnings. Over the last 12 months PMN insiders bought $8.9M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is PMN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PMN.

Key Stats

Last 12 months
Results
Net income
−$38.8M
EPS (diluted)
−$6.42
Valuation
Market cap
$28.4M
9.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$44.1M
At Sep 30
Shareholder equity
$41.8M
Shares outstanding
9.0M
At Nov 12
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$9.8M−$9.8MFY2021FY2022: −$18.1M−$18.1MFY2022FY2023: −$13.2M−$13.2MFY2023FY2024: $2.8M$2.8MFY2024FY2025: −$39.7M−$39.7MFY2025

From PMN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 24
Estimated date · Time not announced
Reported EPS
-$0.89
Quarter ended Sep 2026
Year ago EPS
-$5.93
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $2.50Dec '24Mar 2025: -$5.27Mar '25Jun 2025: -$7.26Jun '25Sep 2025: -$5.93Sep '25Dec 2025: -$3.03Dec '25Mar 2026: -$1.26Mar '26Jun 2026: -$1.28Jun '26Sep 2026: -$0.89Sep '26Latest -$0.89
Revenue by quarter
Not enough quarters on file yet.
How PMN moved after its last 8 reports
Average move the session after a report ±2.7%
Nov 12, 2026After the close−5.5%
Aug 13, 2026After the close+0.5%
May 12, 2026Time not announced−1.8%
Mar 25, 2026Time not announced−9.1%
Nov 12, 2025Time not announced+4.0%
Aug 13, 2025Time not announced0.0%
May 12, 2025Time not announced−0.2%
Mar 31, 2025Time not announced−0.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PMNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on PMN: 0 upgrades, 0 downgrades, 0 initiations
HC WainwrightReiterated
Nov 21  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on PMN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PMN

Technical Analysis

PMN · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 51% below its 20 day and 158% below its 50 day average. It is 290% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 30), near oversold. The nearest support is the Pivot S1 at $2.98, and the nearest resistance the Pivot at $3.17.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 26.7%/day
Key levels
$27.4052 week high+767.1%
$12.31200 day average+289.6%
$11.07100 day average+250.3%
$8.1750 day average+158.5%
$4.7820 day average+51.3%
$4.33Swing high (Nov 6)+37.0%
$3.34Pivot R1+5.7%
$3.17Pivot+0.3%
$3.16Last close
$2.98Pivot S1−5.7%
$2.98Swing low (Nov 13)−5.7%
$2.7852 week low−12.0%
Indicators
RSI (14)30.42Weak, oversold below 30Neutral
MACD-1.53Above its signal lineBullish
Stochastic14.8Near the bottom of its rangeOversold
ADX (14)34.6Trending down
Williams %R-86.7Oversold below −80, overbought above −20Oversold
CCI (20)-56.7Oversold below −100, overbought above 100Neutral
Rate of change−24.0%Change over 10 sessionsBearish
ATR (14)$0.84Typical daily range, 26.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PMN

What happened before

See how PMN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PMN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PMN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PMNHow many large options trades hit PMN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

PMN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲11 buying vs 7 selling
  • ●Held by funds -0.3 pts
  • ▲Funds holding +4
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3127+14.8%
In funds' top 10220.0%
Held by funds70.8%71.2%−0.3 pts
New / increased7 / 44 / 6+10.0%
Reduced / sold out4 / 36 / 2−12.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PMN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PMN Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$8.9M9 buys · 5 insiders
Sold$00 sales · 0 insiders
Cluster buy: 2 insiders bought $135K between Oct 30 and Nov 4.
2026-02 bought $8.5M2026-03 bought $141K2026-04 bought $45K2026-08 bought $30K2026-10 bought $5K2026-11 bought $129KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 4Eugene WilliamsDirectorBuy26,500$3.43$91K
Nov 2Neil CashmanChief Scientific OfficerBuy10,000$3.86$39K
Oct 30Eugene WilliamsDirectorBuy1,316$3.99$5K
Aug 5Johanne KaplanChief Development OfficerBuy2,280$13.30$30K
Apr 22Patrick D. KirwinDirectorBuy4,000$11.33$45K
Mar 5Eugene WilliamsDirectorBuy2,000$24.40$49K
Every insider buy and sale for PMN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PMN insider trades →

From SEC Form 4 filings by PMN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PMN is in one of them and how their past PMN trades turned out.

PMN in the AI portfolios
Loading…

PMN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PMN in an article yet. Here's the latest on the wider market.

PMN in the news

About ProMIS Neurosciences

ProMIS Neurosciences is a biotechnology company based in Toronto, Canada, that is developing antibody therapies for neurodegenerative diseases. Its main program targets Alzheimer's disease, and its other candidates address conditions such as ALS and Parkinson's disease. The company uses a computational platform to find targets that appear only on the harmful, misfolded form of a protein, so its antibodies aim to leave the healthy form alone. The therapies are intended for patients with these conditions, and the company is still in clinical development.

Headquarters
Toronto, Ontario, Canada